Abatacept and Sodium Thiosulfate for Treatment of Recalcitrant Juvenile Dermatomyositis Complicated by Ulceration and Calcinosis

Arabshahi, Bita; Silverman, Robert A.; Jones, Olcay Y.; Rider, Lisa G.

doi:10.1016/j.jpeds.2011.11.057

Cited by 104 publications

(62 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This highlights a limitation of our study because patients received etanercept therapy for only 12 weeks, which may have been insufficient to detect either improvement or worsening of disease activity. A recent report of abatacept and sodium thiosulfate administered to a 14-year-old female with resistant juvenile DM involving calcinosis and ulceration resulted in marked disease improvement (18). Future clinical trials of abatacept, rituximab, and other therapies with a biologic agent in children with juvenile DM are clearly warranted.…”

Section: Discussionmentioning

confidence: 99%

Pilot Study of Etanercept in Patients With Refractory Juvenile Dermatomyositis

Rouster‐Stevens

Ferguson

Morgan

et al. 2014

Arthritis Care & Research

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Pilot Study of Etanercept in Patients With Refractory Juvenile Dermatomyositis

Rouster‐Stevens

Ferguson

Morgan

et al. 2014

Arthritis Care & Research

View full text Add to dashboard Cite

“…Later, an improvement in muscle and skin disease was reported in a patient with juvenile DM complicated by ulceration and calcinosis [69]. Recently, Kerola et al [70] reported a case of a 46-year-old female patient who developed a severe myositis overlap syndrome, including features of RA, peripheral vasculitis and ILD, refractory to different immunosuppressive and biologic drugs.…”

Section: Biologic Therapymentioning

confidence: 98%

Current pharmacological treatment of idiopathic inflammatory myopathies

Fasano

Alves²,

Isenberg

2016

Expert Review of Clinical Pharmacology

View full text Add to dashboard Cite

The idiopathic inflammatory myopathies are uncommon and heterogeneous disorders. Their classification is based on distinct clinicopathologic features. Although idiopathic inflammatory myopathies share some similarities, different subtypes may have variable responses to therapy, so it is very important to distinguish the correct subtype.There are few randomised, double blind placebo controlled studies to support the current treatment.High dose corticosteroids continue to be the first line therapy and other immunosupressive drugs are used in refractory cases, as well as steroid-sparing agents.Some novel therapeutic approaches have emerged as potential treatment including tacrolimus, intravenous immunoglobulin and rituximab, following good outcomes reported in case studies.However, more randomised controlled trials are needed.This review considers the current and the potential future therapies for inflammatory myopathies.

show abstract

“…A recently published review of current pharmacological treatment of idiopathic inflammatory myopathies [69] described three cases of refractory myositis treated with tocilizumab with promising results [118][119][120] and three case reports showing beneficial effects of co-stimulation blockade using Abatacept in myositis [121][122][123]. A randomized clinical trial is underway to test this hypothesis (ClinicalTrials.gov Identifier: NCT02594735).…”

Section: Other Biologic Agentsmentioning

confidence: 99%

Treatment of Juvenile Dermatomyositis: An Update

Papadopoulou

Wedderburn

2017

Pediatr Drugs

View full text Add to dashboard Cite

Abstract:The Idiopathic Inflammatory Myopathies of childhood consist a heterogeneous group of autoimmune diseases characterised by proximal muscle weakness and pathognomonic skin rashes. The overall prognosis of juvenile myositis has improved significantly over recent years, but the long-term outcome differs substantially from patient to patient suggestive of distinct clinical phenotypes with variable responses to treatment. High doses of corticosteroids remain the cornerstone of therapy along with other immunosuppressant therapies depending on disease severity and response. The advent of biological drugs has revolutionised the management of various paediatric rheumatologic diseases, including inflammatory myopathies. There are few data from randomised controlled trials to guide management decisions, thus several algorithms for the treatment of juvenile myositis have been developed using international expert opinion. The general treatment goals now include elimination of active disease and normalization of physical function, so as to preserve normal growth and development, and to prevent long-term damage and deformities. This review summarizes the newer and possible future therapies of juvenile inflammatory myopathies, including evidence supporting their efficacy and safety.

show abstract

Abatacept and Sodium Thiosulfate for Treatment of Recalcitrant Juvenile Dermatomyositis Complicated by Ulceration and Calcinosis

Cited by 104 publications

References 11 publications

Pilot Study of Etanercept in Patients With Refractory Juvenile Dermatomyositis

Pilot Study of Etanercept in Patients With Refractory Juvenile Dermatomyositis

Current pharmacological treatment of idiopathic inflammatory myopathies

Treatment of Juvenile Dermatomyositis: An Update

Contact Info

Product

Resources

About